Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 5/20 | 0.59 |
| ▸ | PGK2 | P07205 | 5/20 | 0.59 |
| ▸ | PTPRB | P23467 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824567 | 0.80 | PGK1 (0.76) | PGK1PGK2PTPRBACP3 | |
| SCHEMBL19794310 | 0.80 | ENPP2 (0.36) | ENPP2HCAR2 | |
| SCHEMBL27718055 | 0.76 | ENPP2 (0.62) | PGK1PGK2PTPRBENPP2 | |
| SCHEMBL915312 | 0.76 | PGK1 (0.48) | PGK1PGK2PTPRBENPP2THRA | |
| SCHEMBL5798610 | 0.73 | PGK1 (0.55) | PGK1PGK2PTPRBTHRATHRB | |
| SCHEMBL27553338 | 0.72 | HCAR2 (0.45) | HCAR2 | |
| SCHEMBL26544979 | 0.72 | PGK1 (0.64) | PGK1PGK2PTPRBTHRATHRB | |
| SCHEMBL5660361 | 0.71 | PGK1 (0.52) | PGK1PGK2PTPRB | |
| SCHEMBL8199992 | 0.71 | PTGS2 (0.53) | PGK1PGK2PTPRB | |
| SCHEMBL22973707 | 0.70 | PGK1 (0.61) | PGK1PGK2PTPRBACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550095-B2 | Cancerous cell growth inhibiting compounds | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170342047-A1 | Cancerous Cell Growth Inhibiting Compounds | WISYS TECHNOLOGY FOUNDATION, INC. | 2017-11-30 | — | — | US | disclosed |
| US-8530512-B2 | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | MONTE AARON P (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | MONTE AARON P | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342047-A1 | Cancerous Cell Growth Inhibiting Compounds | TYR, MKI67, MC1R | PGK1 545/4885PGK2 673/4885PTPRB 1536/4885 |
| US-10550095-B2 | Cancerous cell growth inhibiting compounds | TYR, MKI67, MC1R | PGK1 545/4885PGK2 673/4885PTPRB 1536/4885 |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | ABCC1, H1-3, H1-2 | PGK1 3026/4885PGK2 3313/4885PTPRB 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.